TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer

NCT ID: NCT01060423

Last Updated: 2016-10-26

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-02-28
• Study Completion Date: 2015-05-31

Brief Summary

The primary objective of this study is to evaluate the efficacy of Irinotecan Beads in combination with intravenous cetuximab versus intravenous irinotecan in combination with intravenous cetuximab in the treatment of patients with unresectable liver metastases from colorectal cancer.

Secondary objectives are safety and tolerability of hepatic chemoembolization and the question if the addition of aprepitant to standard antiemetic prophylaxis in patients treated by hepatic chemoembolization is safe and will reduce the rate of acute and delayed nausea and emesis.

Detailed Description

About half of patients with newly diagnosed colorectal cancer will develop metastatic disease and, however, in spite of the significant progress in the therapeutical strategies for metastatic disease, virtually all patients will eventually succumb to their illness. Based on prior clinical data there is a good rationale for the expectation that the combination of systemic chemotherapy and arterial chemoembolization with drug eluting beads may be effective in the setting of patients with unresectable or chemorefractory liver metastases. The aim of this study is therefore to assess whether the combination of Irinotecan eluting beads and intravenous cetuximab is safe and effective in the treatment of patients with unresectable liver metastases from refractory colorectal cancer and will result in a prolongation of disease control when compared to standard systemic treatment with intravenous irinotecan and intravenous cetuximab. In this patient group, intravenous irinotecan plus intravenous cetuximab may represent the "standard of care", with a previously described activity. The patient group is defined in terms of pretreatment, and the scientific question is whether the way of irinotecan administration by eluting beads in feasible and somehow beneficial.

Conditions

Colorectal Cancer

Keywords

colorectal; liver metastasis; KRAS wildtype; chemoembolization; irinotecan eluting beads

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

hepatic TACE with irinotecan eluting beads and iv cetuximab

Irinotecan drug-eluting beads administered by hepatic chemoembolization with intravenous cetuximab (DEBIRITUX)

Group Type: EXPERIMENTAL

Cetuximab

Intervention Type: DRUG

Starting dose of 400mg/m2, followed by weekly 250mg/m2

Irinotecan eluting BEADS

Intervention Type: DEVICE

A minimum of two treatments per lobe (four bi-weekly sessions in the event of bilobar disease) at week 0 and 4 with up to 4ml (100-300µm DC Bead loaded with up to 200mg irinotecan) will be scheduled (i.e. for bilobar disease right lobe: week 0, left lobe: week 2, right lobe: week 4 and left lobe: week 6: following toxicity and extending interval if toxicity seen).

iv cetuximab and irinotecan

systemic treatment with intravenous cetuximab and irinotecan

Group Type: ACTIVE_COMPARATOR

Cetuximab

Intervention Type: DRUG

Starting dose of 400mg/m2, followed by weekly 250mg/m2

Irinotecan

Intervention Type: DRUG

Irinotecan 180 mg/m² to be administered every two weeks

Interventions

Cetuximab

Starting dose of 400mg/m2, followed by weekly 250mg/m2

Intervention Type: DRUG

Irinotecan

Irinotecan 180 mg/m² to be administered every two weeks

Intervention Type: DRUG

Irinotecan eluting BEADS

A minimum of two treatments per lobe (four bi-weekly sessions in the event of bilobar disease) at week 0 and 4 with up to 4ml (100-300µm DC Bead loaded with up to 200mg irinotecan) will be scheduled (i.e. for bilobar disease right lobe: week 0, left lobe: week 2, right lobe: week 4 and left lobe: week 6: following toxicity and extending interval if toxicity seen).

Intervention Type: DEVICE

Other Intervention Names

Erbitux; DC Bead

Eligibility Criteria

Inclusion Criteria

1. Patients with confirmed diagnosis of stage IV (UICC) colorectal cancer with unresectable liver metastases (primary tumour may be present) and k-ras wild-type tumours

2. Patients had been treated and shown to be refractory to 5-FU (Capecitabine allowed)/oxaliplatin and/or 5-FU/irinotecan. Prior therapy with VEGF-inhibitors (e.g bevacizumab) is allowed

3. Patients with at least one measurable liver metastasis, with size > 1cm (RECIST criteria)

4. Patients with liver only or liver dominant disease (defined as ≥ 50 % tumour burden confined to the liver)

5. Patients with a portal vein not interfering with transarterial chemoembolization (e.g. no thrombosis) as judged by the investigator

6. ECOG Performance status ≤ 2

7. Life expectancy > 3 months

8. Age ≥ 18 years.

9. At least 4 weeks since last administration of last chemotherapy and/or radiotherapy (bone metastases may be allowed)

10. Patients who received VEGF-inhibition (e.g. with bevacizumab) in prior therapy are eligible if stopped since 4-6 weeks before randomization

11. Haematologic function: ANC ≥ 1.5 x 109/L, platelets ≥ 75 x109/L

12. INR < 1.5 (patients on therapeutic anticoagulants are not eligible)

13. Adequate liver function as measured by serum transaminases (AST & ALT) ≤ 3 x ULN and total bilirubin ≤ 1.5 x ULN

14. Adequate renal function: Serum creatinine ≤ 1.5 x ULN

15. Normal level of serum magnesium

16. Women of child bearing potential and fertile men are required to use effective contraception (negative serum βHCG for women of child-bearing age

17. Signed, written informed consent

Exclusion Criteria

1. Presence of CNS metastases

2. Contraindications to irinotecan therapy (Chronic inflammatory bowel disease and/or bowel obstruction, history of severe hypersensitivity reactions to irinotecan hydrochloride trihydrate)

3. Active bacterial, viral or fungal infection within 72 hours of study entry

4. Women who are pregnant or breast feeding

5. Allergy to contrast media

6. Presence of another concurrent malignancy. Prior malignancy in the last 5 years except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix

7. Any contraindication for hepatic embolisation procedures:

• Large shunt as determined by the investigator (pretesting with lung perfusion scan not required)
• Severe atheromatosis
• Hepatofugal blood flow

8. Other significant medical or surgical condition, or any medication or treatment, that would place the patient at undue risk, that would preclude the safe use of chemoembolization or would interfere with study participation

9. Known hypersensitivity or contraindication to the drugs used in the trial (eg: cetuximab, 5-HT3 receptor antagonist, dexamethasone, or any component of aprepitant)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Biocompatibles UK Ltd

INDUSTRY

Sponsor Role: collaborator

Hans-Joachim Schmoll, MD

OTHER

Sponsor Role: lead

Responsible Party

Hans-Joachim Schmoll, MD

MD

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Dirk Arnold, MD

Role: PRINCIPAL_INVESTIGATOR

Universitätsklinikum Eppendorf, Universitäres Cancer Center

Locations

Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden

Dresden, Dresden, Germany

Zentralklinik Bad Berka GmbH, Abteilung für Interventionelle Radiologie

Bad Berka, , Germany

Kliniken Essen-Mitte, Klinik für Innere Medizin IV

Essen, , Germany

Klinikum Esslingen, Klinik für Onkologie, Gastroenterologie und Allgemeine Innere Medizin

Esslingen am Neckar, , Germany

Krankenhaus Nordwest

Frankfurt/M., , Germany

Universitätsklinikum der Johann Wolfgang Goethe Universität Frankfurt

Frankfurt/M., , Germany

Martin-Luther-Universität Halle-Wittenberg

Halle, , Germany

Universitätsklinikum Hamburg-Eppendorf

Hamburg, , Germany

SLK-Kliniken Heilbronn

Heilbronn, , Germany

Otto-von-Guericke-Universität Magdeburg

Magdeburg, , Germany

Universitätsklinikum Regensburg

Regensburg, , Germany

Universitätsklinikum Tübingen, Medizinische Klinik und Poliklinik II

Tübingen, , Germany

Universitätsklinikum Würzburg, Institut für Röntgendiagnostik

Würzburg, , Germany

Countries

Germany

Other Identifiers

EudraCT: 2009-014728-44

Identifier Type: -

Identifier Source: org_study_id